Biota Biosciences announced the voluntary recall of CBD Complex, Curcumin Complex, and Cannabidiol + Curcumin Injectables due to the products being marketed without the approval of the FDA.
During COVID-19, clinicians will be challenged by a lack of ICU resources and ventilators to manage patients with status epilepticus.
A brief communication provides information about the associations between, and the considerations for, COVID-19 and epilepsy.
The STOPBAG2 scoring instrument, which incorporates sleep-related symptoms and continuous variables for age and BMI, offers greater discriminatory power for predicting all levels of OSA severity in adults with epilepsy.
Add-on cannabidiol was found to be safe and effective for patients with Lennox Gastaut Syndrome.
Individuals with vs without status epilepticus were found to have a greater prevalence of cardiovascular risk factors and a higher risk of developing cardiovascular diseases.
Epidiolex® (cannabidiol; GW Pharmaceuticals) oral solution is no longer a controlled substance, according to the Drug Enforcement Administration.
The FDA has accepted for Priority Review the supplemental New Drug Application for Epidiolex.
Investigators assessed the efficacy and safety of 2 daily doses of cannabidiol, 10 mg/kg or 20 mg/kg, in children with Dravet syndrome.
The DEA has designated Xcopri (cenobamate; SK Life Science) as a schedule V controlled substance, indicating a lower potential for abuse.
